POSA108 A Budget Impact Analysis of Atezolizumab Monotherapy for First Line Treatment of Patients with PD-L1 High Metastatic NSCLC in Italy

Abstract

Lung cancer is the second most common cancer and the leading cause of cancer death worldwide. Atezolizumab as monotherapy was approved by EMA in April 2021 for the first line treatment of adult patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors have PD-L1 expression ≥ 50% and who do not have EGFR mutant or ALK-positive NSCLC. The objective of this analysis is to estimate the potential budget impact of atezolizumab over a three-year time horizon from the National Healthcare Service (NHS) perspective in Italy.